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osting by EAbstract Fats and lipids are common components of food and may perform essential roles. Their
types may be more important with regard to health and disease than their amount. The objective of
this review is to summarize the information on the role of functional lipids on human health. New
research has linked functional lipids to the prevention and treatment of many diseases. Functional
lipids such as omega-3 and omega-6 fatty acids, conjugated linoleic acids, medium chain triglycer-
ides, and phytosterols have many beneﬁcial effects on human health such as in obesity, bone health,
and in treating and managing depression, blood pressure, cardiovascular health, etc. The ratio of
omega-3 and omega-6 polyunsaturated fatty acids regulates the production of eicosanoids, which
are the metabolites of these series of fatty acids. Scientiﬁc evidence has shown encouraging improve-
ments in patients and beneﬁcial effects in healthy persons with the use of supplemental and dietary
forms of functional lipids.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Foods can be regarded as functional if they help in reducing
the risk of disease and promote good health (Roberfroid,
2000). They may provide means to reduce the increasing bur-4785968x1484, mobile: +966
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lsevierden on the health care system. Although there is no authorita-
tive deﬁnition of functional lipids, one can informally deﬁne
them as a subset of functional foods, which are considered
to be similar in appearance to conventional foods consumed
as part of a usual diet, but they have been demonstrated to
have physiological beneﬁts and/or reduce the risk of chronic
disease beyond basic nutritional functions (Moreau, 2011).
The purpose of this review is to summarize the information
currently available on selected functional lipids.2. Components of functional lipids
The following are considered as functional lipids: omega-3
fatty acids (alpha-linolenic acid (ALA), eicosapentaenoic acid
(EPA), docosahexaenoic acid (DHA)), omega-6 fatty acids
(gamma linoleic acid (GLA), and linoleic acid (LA)), conju-
gated linoleic acid (CLA), medium chain triglyceride oils,
and phytosterols.
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Humans can synthesize saturated and monounsaturated fatty
acids but cannot synthesize polyunsaturated omega-3 (also re-
ferred to as x-3 or n-3) and omega-6 (also referred to as x-6 or
n-6) fatty acids de novo. This is because humans like other ani-
mals, lack the desaturase enzymes required to produce the sim-
plest members of these families (ALA and LA, respectively).
Thus ALA and LA are considered ‘‘essential fatty acids’’
(EFAs) that need to be included in the diet. EFAs act as pre-
cursors for the synthesis of more highly unsaturated and long-
er-chain omega-3 and omega-6 fatty acids (Tapiero et al.,
2002).Omega-3 and x-6 fatty acids are essential components
of cell-membrane phospholipids and they have several other
functional roles (Hardman, 2004).2.1.1. Omega-3 fatty acids
2.1.1.1. Alpha-linolenic acid (18:3 (x-3); all-cis-9,12,15
octadecatrienoic acid; ALA). ALA is mainly of plant origin and
is the precursor of two functionally important longer-chain x-3
fatty acids, eicosapentaenoic acid (EPA; 20:5 (x-3)) and docosa-
hexaenoic acid (DHA; 22:6 (x-3)). Conversion efﬁciency of
ALA to EPA and DHA is low (Igarashi et al., 2006; Williams
and Burdge, 2006; Kapoor and Patil, 2011) and is estimated to
be approximately 4–5% (Brenna, 2002) inmen, but greater than
this in women (Burdge, 2004). More generally, there are several
ways to express the conversion rate and it probably depends on
the tissues which are investigated. Furthermore, the turnover of
EPAandDHAmust be considered. Some studies (Umhau et al.,
2009) suggested that the half life of DHA in the human brain
may exceed several months and even as long as two years. If
these data are conﬁrmed than it means that inﬂuence of food
must be considered over a long time range.2.1.1.2. Eicosapentaenoic acid (20:5 (x-3); all-cis-5,8,11,14,17
eicosapentaenoic acid; EPA) and docosahexaenoic acid (22:6
(x-3); all-cis-4,7,10,13,16,19 docosahexaenoic acid; DHA).
These are long-chain, polyunsaturated fatty acids naturally
found in aquatic foods, especially oily ﬁsh and in ﬁsh oil sup-
plements. DHA is highly abundant in brain (Sastry, 1985) and
retina (Dratz and Holte, 1993) where it plays important struc-
tural and functional roles. Consequently, DHA status is
important to ensure optimum neural and visual functions
(Innis, 2003; Birch et al., 2007; Eilander et al., 2007). EFAs
are the precursors of a family of prostaglandins and leukotri-
enes, which control blood clotting and other arterial functions
and inﬂammation (Simopoulos, 2002; Mori and Beilin, 2004).
This may be important in reducing the risk of cardiovascular
disease (Angerer and Von Schacky, 2000; Jacobson, 2008).
Prostaglandins produced from EPA constitute a minor group
compared to eicosanoids produced from arachidonic acid
(AA) and may be as much as one hundred fold less potent bio-
logically for inducing pro-inﬂammatory cellular responses
than those derived from AA (Robinson et al., 1988). EPA
and DHA also lower blood triglyceride concentrations (Harris,
1997) and are substrates for the synthesis of resolvins, which
are believed to play a key role in terminating inﬂammatory
processes (Kohli and Levy, 2009). Thus these x-3 fatty acids
could be important in treating inﬂammatory diseases (Mori
and Beilin, 2004).2.1.2. Omega-6 fatty acids
2.1.2.1. Gamma linoleic acid (18:3 (x-6); all-cis-6,9,12
octadecatrienoic acid; GLA). GLA is produced in the body as
an intermediate in the metabolism of LA by the enzyme delta-6
desaturase. This reaction is the rate limiting step in the conver-
sion of LA into its more unsaturated and longer derivatives
(Horrobin, 1992; Cheng et al., 2004). GLA is also found in
some plant oils. GLA is rapidly elongated to dihomogammali-
nolenic acid (20:3 (x-6); DGLA) by the enzyme elongase. Sub-
sequently, DGLA may be incorporated into cell-membrane
phospholipids or may be converted into arachidonic acid
(20:4 (x-6); AA) by the enzyme delta-5-desaturase. AA is
one of the most important fatty acids associated with mem-
brane phospholipids. AA can be oxidized to a variety of eicos-
anoid compounds important in cell–cell signalling (Wheelan,
1996).
2.2. Conjugated linoleic acid (main isoform is cis-9, trans-11-
octadecadienoic acid; CLA)
CLA refers to a group of polyunsaturated fatty acids (PUFA)
that exist as positional and stereo-isomers of linoleic acid with
a conjugated double bond. Many forms of CLA are possible
(Sehat et al., 1999). The major naturally occurring CLA is
cis-9, trans-11 CLA, found in ruminant milks, dairy products
and ruminants’ meats and also in CLA supplements. Animal
models suggest that some CLA isomers have a role in prevent-
ing cancer (Ip et al., 1994). There are suggestions that CLA has
a role in treating some human diseases (Nagao and Yanagita,
2005).
2.3. Medium chain triglycerides
Medium chain triglyceride (MCTs) contains fatty acids with
6–10 or 12 carbon atoms in their acyl chain. MCTs are readily
digested, not requiring bile salts, and the shorter fatty acids are
transported in bloodstream without the need for lipoproteins
(Stein, 1999). Hence they are directed to the liver for metabo-
lism. Their oxidation does not require carnitine (Bach and
Babayan, 1982). Hence MCTs and their constituent fatty acids
are useful as a fat source to those with the abnormalities of fat
digestion, absorption, transport and metabolism (Smits et al.,
1968; Marten et al., 2006).
2.4. Phytosterols
Phytosterols (plant sterols) are common plant and vegetable
constituents. They are normal constituents of the human diet
and are considered to be biologically active (Pirronen et al.,
2000). They are structurally related to cholesterol, but differ
from cholesterol in the structure of the side chain. Examples
are campesterol, stigmasterol and beta-sitosterol. Phytosterols
inhibit cholesterol absorption and so help to control blood to-
tal cholesterol, LDL and HDL levels and so modify the risk of
cardiovascular disease (Lichtenstein and Deckelbaum, 2001).
3. Omega-6 to omega-3 ratio of the diet
The healthy ratio of x-6 to x-3 fatty acids in the human diet is
said to range from 1:1 to 4:1 (Simopoulos et al., 2000; Simopo-
ulos, 2003). Due to the excessive use of vegetable oil, rich in
Figure 1 Biosynthesis pathways of omega-3 and omega-6 PUFA and oxidative metabolism of arachidonic and eicosapentaenoic acid by
carboxygenase (COX) and 5 Lipoxygenase pathways (LOX), where 5 HPETE denotes 5 hydroperoxyeicosatetraenoic acid, 5HPEPE
denotes 5 hydroxyeicosapentaenoic acid, d-6-d denotes delta-6 desaturase and d-5-d denotes delta-5 desaturase. A fatty acid notation
represents total number of carbons: number of double bonds, position of the ﬁrst double bond relative to methyl terminal of the
hydrocarbon chain (adapted from San Giovanni and Chew, 2005; Simopoulos, 2010 with modiﬁcation).
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duced intake of ﬁsh, this ratio is now higher, in most western
diets (Kris-Etherton et al., 2002). LA and ALA compete for
the same enzymes for conversion to AA and EPA, respectively.
Hence the ratio between LA and ALA will partly determine
the availability of the biologically active products, AA and
EPA. In turn AA and EPA compete for the same enzymes
for eicosanoid synthesis and so the ratio between AA and
EPA may inﬂuence blood clotting, smooth muscle contraction,
inﬂammation and immune responses (Simopoulos, 1991;
Simopoulos 2008b) (Fig. 1).
4. Dietary sources of functional lipids and recommendations for
their intake
Dietary sources of functional lipids are listed in Table 1. The
World Health Organization recommends (for adults), a total
x-3 fatty acid intake of 0.5–2% of energy and a total x-6 fatty
acid intake of 2.5–9% of energy. For adult males and non-
pregnant/non-lactating adult females 0.250 g/day of EPA plusDHA is recommended, with insufﬁcient evidence to set a spe-
ciﬁc minimum intake of either EPA or DHA alone; both
should be consumed. For adult pregnant and lactating females,
the minimum intake for optimal adult health and foetal and in-
fant development is 0.3 g/d EPA+ DHA, of which at least
0.2 g/d should be DHA (FAO, 2008). There are no dietary rec-
ommendations for MCTs, CLA or phytosterols. However, a
safety factor for free phytosterols has been estimated to be
137 mg/kg/day, equivalent to 9.6 g/person/day for a 70 kg
adult (ACNFP, 2002a).
5. Roles of functional lipids on health
5.1. Obesity
Obesity and overweight are increasing in epidemic proportions
throughout the developed and developing world and are one of
the most important growing threats to the health of popula-
tions. Obesity management is a modern challenge especially
in most of the developed countries and there is a need for effec-
Table 1 Dietary source of functional lipids.
Functional
lipids
Dietary sources
Omega-3 fatty
acid
Eicosapentaenoic acid and docosahexaenoic acid: Fatty ﬁsh such as mackerel,
sardine, tuna and micro algae
Alpha linolenic acid: Dark green leafy vegetables, ﬂax seed oil, chia seed oil,
egg, meat, lingon berry, sea buckthorn, hemp seed oil, canola oil, walnuts,
hazelnuts
Omega-6 fatty
acid
Linoleic acids: Vegetable oil, salad dressing, nuts
Gamma linolenic acid: Black currant oil, evening primrose oil, borage oil
Conjugated
linoleic acid
Milk, meats (kangaroo meat), grass fed ruminants, egg yolk, ﬁsh, fresh
ground beef, butter fat, plain yogurt, cultured buttermilk, custard style
yogurt, cheddar cheese
Medium chain
triglycerides
Animal fat, palm oil, coconut oil, cocoa butter
Phytosterols Wheat germ, corn oil, canola oil, almonds, brussels, sprouts, ﬂaxseed, peanut
butter, cauliﬂower, olive oil, sesame seeds
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a healthy balanced diet or increasing physical activity appears
quite difﬁcult for many individuals to follow. Many studies
investigating the effects of functional lipids on weight loss
show impressive results. In a three week study in twenty se-
verely obese women, addition of x-3 PUFA to a very low cal-
orie diet (VLCD) resulted in greater weight and hip
circumference losses, and a greater increase in fatty acid oxida-
tion and in ketogenesis compared to control group undergoing
the VLCD only (Kunesova et al., 2006). Fish oil improved sati-
ety in overweight and obese volunteers (Parra et al., 2008). In
young overweight subjects, 8 weeks of a calorie-restricted diet
that included ﬁsh or supplemental ﬁsh oil resulted in a greater
reduction of adipose tissue and of weight than in the calorie-re-
stricted control group (Thorsdottir et al., 2007).
There are some studies which suggest that CLA supplemen-
tation reduces body weight, adiposity and plasma leptin con-
centration (Smedman and Vessby, 2001). However, although
such effects are seen commonly in laboratory animals, the ﬁnd-
ings in humans are less consistent and less signiﬁcant (Ryder
et al., 2001). A double-blind, placebo-controlled randomized
trial in 26 men and 28 women who received 1.8 g CLA (mix-
ture of equal amounts of c9, t11 and t10, c12) or placebo per
day or 3.6 g CLA (mixture of equal amounts of c9, t11 and
t10, c12) or placebo per day, showed that appetite (hunger,
satiety and fullness) was favourably and dose-independently
suppressed by CLA for 13-weeks consumption but it did not
translate into in a lower energy intake at breakfast or an im-
proved body-weight maintenance after weight loss (Kamphuis
et al., 2003). Another double-blind design on 22 volunteers
indicated that supplementation with 0.7–1.4 g CLA for 4–
8 weeks may modulate body fat and serum lipids in humans
(Mougios et al., 2001). Larsen et al. (2006) in their one year
long double-blind study on one hundred one subjects found
that 3.4 g CLA (39% c9, t11 and 41% t10, c12) per day did
not prevent weight or fat mass regain in a healthy obese pop-
ulation. In a bicentric, placebo-controlled, double-blind, ran-
domized study, consumption of a drinkable dairy product
containing up to 3 g of CLA isomers (c9, t11 or t10, c12) for
18 weeks had no statistically signiﬁcant effect on body compo-sition in overweight, middle-aged men and women (Malpuech-
Brugere et al., 2004). The above data depict the less signiﬁcant
and inconsistent effects of CLA on body weight and composi-
tion in humans.
Unlike long-chain triglycerides, MCTs are energetically less
dense and provide on average 8.0 kcal/g of metabolized energy
as compared with an average of 9.0 kcal provided by long-
chain triglycerides (LCTs). The rapid oxidation of MCTs pro-
motes greater ketone body formation which can also be used
by the brain as energy source, decreases hunger and increases
protein synthesis (Baba et al., 1982; Hoffer et al., 1984; Bach
et al., 1996). Increased thermo genesis promoted by MCTs
has a lipolytic effect (Krotkiewski, 2001) and so can improve
the long-term success of diet therapy of obese patients. In a
randomized double-blind study on sixty-six obese women with
body mass index (BMI) > 30 kg/m2, 22 were randomly as-
signed to the control group (VLCD with low fat content)
and the remaining 44 were pair-matched VLCD+MCT or
VLCD+ LCT for a period of four weeks. The MCT group,
showed a greater decrease of body fat, body weight and lower
intensity of hunger feelings. These changes were observed only
for a period of two weeks and gradually declined, indicating
subsequent metabolic adaptation (Krotkiewski, 2001). Phytos-
terols have also shown a positive effect in decreasing obesity in
animals (Awika and Rooney, 2004; Ebine et al., 2006; Thorn-
ton et al., 2011). However, there is a lack of information about
ﬁndings in humans.
5.2. Plasma lipid concentrations
The plasma lipid proﬁle is a very important factor that has to
be taken into account while considering dietary fat and qual-
ity. Studies suggest the beneﬁcial effects of long-chain x-3
PUFA in preventing sudden death following myocardial
infarction (Lee and Lip, 2003; Leaf et al., 2003) and that they
may even be superior to statins in secondary prevention
(Bhatnagar and Durrington, 2003). Omega-3 fatty acids co-
administered with statins have synergistic and additive effects
on plasma lipids (Vrablik et al., 2009). In general PUFA are
considered as hypocholesterolemic and hypotriglyceridemic
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different PUFAs have different effects. For example LA is
cholesterol and LDL cholesterol lowering whereas marine
x-3 PUFAs are not. There are studies which show a cardio
protective effect (such as reduction in hypertryglyceridemia)
of x-3 (60% x-3 PUFA content, EPA/DHA= 3/2) fatty acids
in the patients on haemodialysis (Taziki et al., 2007) and with
chronic renal failure (Svensson et al., 2004). In these studies
the consumption of 2 g of PUFA (x-3) per day for 12 weeks
(Taziki et al., 2007) or 2.4 g for 8 weeks (Svensson et al.,
2004), respectively, resulted in a signiﬁcant increase in high-
density lipoprotein cholesterol levels and a signiﬁcant decrease
in serum triglyceride levels without any changes in total choles-
terol or low-density lipoprotein cholesterol levels.
Some studies suggest that MCTs in the diet decrease choles-
terol and triglyceride concentrations (Marten et al., 2006), but
other studies have indicated that diets containing MCT oil can
increase blood cholesterol levels (Cater et al., 1997). The safety
of medium chain triacylglycerol in dietary oil has been de-
bated, and related effects on cholesterol metabolism remain
unclear (Kitts, 2005). In most of the human studies with
CLA, no major effect on blood lipid concentrations was seen
(Terpstra, 2004). Phytosterols even at very low dose of
0.45 g/day (as free sterol) were found to lower the blood total
cholesterol and remnant-like lipoprotein, cholesterol concen-
trations which may be helpful in reducing the risk of CHD
in the population (Seki et al., 2003). Law (2000) in his review
has mentioned that margarines containing plant sterols and
stanols play an important role in the prevention of ischaemic
heart disease. In a meta-analysis it has been found that plant
sterols/stanols added to fat spreads, mayonnaise, salad dress-
ings, milk, or yogurt were more effective in reducing LDL cho-
lesterol levels compared to when plant sterols/stanols were
incorporated into other products, such as chocolate, juice,
cheese and cereal bars (AbuMweis et al., 2008). Eussen et al.
(2011) in his analysis found that phytosterol/-stanol-enriched
margarines can modestly reduce serum total cholesterol in
the community. The effectiveness of these margarines cannot
equalize the effect of cholesterol lowering drugs, but they
can act additively.
5.3. Depression
Depression is a condition in which the patient experiences a
variety of symptoms such as feeling of worthlessness, helpless-
ness or hopelessness, fatigue and even suicidal thoughts, and is
a cause of concern which is increasing all over the world.
According to WHO, depression affects 121 million people
worldwide and is considered as the fourth largest contributor
to global burden of disease (WHO, 2011). Fatty acids play
an important role in brain cell structure as 36–60% of nervous
tissue in brain are lipids which include glycerophospholipids
rich in DHA and AA, sphingolipids, cholesterol and its esters
(McNamara and Carlson, 2006) which inﬂuence the activities
of membrane-linked functional molecules. In the brain DHA
plays signiﬁcant role in (1) membrane related events such as
regulation of membrane bound enzymes and glucose uptake,
signal transduction, regulation of dopaminergic and serotoner-
gic neurotransmission, (2) metabolic events such as regulation
of synthesis of eicosanoids derived from AA, (3) cellular events
such as regulation of neuron size and nerve growth factor,stimulation of cell membrane expansion by action on syntaxin
and stimulation of neurite growth in hippo campal cells and (4)
regulation of gene expression (Sinclair et al., 2007). There are
various epidemiological studies which show an inverse rela-
tionship between the consumption of x-3 fatty acids and inci-
dence of depression (Stahl et al., 2008). The proposed
mechanism of action of x-3 PUFA in mood disorders includes
effects on the biophysical properties of synaptic membranes
which affects neurotransmitter receptors, and effects on
inﬂammatory responses involving eicosanoids (Sinclair et al.,
2007; Stahl et al., 2008). Phospholipids are essential for neuro-
nal and synaptic structures. It plays important roles in the sig-
nal transduction responses to dopamine, serotonin, acetyl
choline and glutamate (Horrobin, 2001). The cyclic adenosine
monophosphate (cAMP) signal transduction suggests that
depression may be caused by an impaired phospholipids
metabolism (Horrobin and Bennett, 1999). The ﬁrst trial of
EPA (puriﬁed ethyl eicosapentaenoate at a dose 4 g daily)
showed marked beneﬁts in treating depression (Puri, 2005).
After 9 months of treatment, symptoms such as low esteem,
insomnia, sadness, inner tension, poor appetite, suicidal
thoughts had disappeared altogether. Low dietary intake
and/or tissue levels of x-3 PUFAs especially lower DHA is
associated with both non-puerperal and post partum depres-
sion (Levant, 2010).5.4. Alzheimer’s disease
Alzheimer’s disease is a progressive neurodegenerative disor-
der which is characterized clinically by the formation of amy-
loid plaque in the brain and nerve cell degeneration (Maccioni
et al., 2001). Data from a cross sectional study among 1613
subjects aged 45 to 70 years showed that dietary consumption
of marine x-3 PUFA (EPA and DHA) was inversely related to
the risk of impaired overall cognitive function (memory func-
tion, cognitive ﬂexibility) and speed of cognitive process (Kal-
mijn et al., 2004). Epidemiological studies suggest a protective
role of x-3 PUFA against Alzheimer’s disease (Morris et al.,
2003; Barberger- Gateau et al., 2011). In humans, ﬁsh con-
sumption or administration of DHA has been associated with
cognitive improvement in some (Barberger-Gateau et al., 2002)
but not all, studies (Morley and Banks, 2010). Fotuhi et al.
(2009) conducted a systematic review of the literature to estab-
lish the association between eating ﬁsh (a source of long-chain
x-3 fatty acids) or taking long-chain x-3 fatty acid supple-
ments and the risk of cognitive decline or Alzheimer’s disease.
It has been reported in this review that long-chain x-3 fatty
acids play a role in slowing cognitive decline in elderly individ-
uals without dementia, but not for the prevention or treatment
of dementia (including Alzheimer’s disease). No signiﬁcant ef-
fect of EPA (500 mg for 12 weeks) was found on the cognition
of patients with Alzheimer’s disease (Boston et al., 2004). Sev-
eral clinical trials investigating the effects of x-3 fatty acid sup-
plementation in Alzheimer’s disease suggest that the beneﬁcial
effects of x-3 fatty acid supplementation may depend on the
dosages, the ratio of long-chain x-3 to x-6 fatty acids (Fotuhi
et al., 2009), stage of disease and apolipoprotein E status (Jicha
and Markesbery, 2010). More clinical studies are required to
fully elucidate the roles and utility of EPA and DHA in the
treatment of Alzheimer’s disease.
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Parkinson’s disease is a brain disorder that results from nerve
damage in certain regions of the brain causing muscle rigidity,
resting tremor, gait disturbance and postural instability
(Olanow and Tatton, 1999; Losso, 2003). An immunohistolog-
ical study found that a small synaptic protein called alpha-syn-
uclein, responsible for neurodegeneration is the main
component of Lewy bodies in the brain of Parkinson’s disease
patients (Spillantini et al., 1997). Oxidative stress andmitochon-
drial dysfunction are the contributing factors of Parkinson’s dis-
ease (Miller et al., 2009; Su et al., 2010). De Lau et al. (2005) in
the Rotterdam study suggested that high intake of unsaturated
fatty acids might protect against Parkinson disease but Chen
et al. (2003) did not ﬁnd any association between x-3 PUFA
intake and Parkinson’s disease.
5.6. Bone health
Bone is a living tissue which is constantly renewed and bone
health plays a very important role in providing mobility and
protection from falls and injury. Long chain PUFA have been
found to be beneﬁcial as they play an important role in bone
metabolism and in bone health. Omega-3 fatty acids have been
shown to enhance the activity of osteoblasts and to inhibit the
activity of osteoclasts (Watkins et al., 2003; Sun et al., 2003).
Osteoblasts produce and mineralize while osteoclasts cause
bone resorption; both are involved in bone modelling and
remodelling and function in a coordinated way throughout
life. Activities of bone formation and bone resorption are lo-
cally regulated by eicosanoids, cytokines and growth factors
and systemically through hormones such as thyroid stimulat-
ing hormone, estrogen, progesterone and testosterone (Ng
et al., 1997; Hadjidakis and Androulakis, 2006). Leukotrienes
are the stimulators of bone resorption (Gallwitz et al., 1993)
and they inhibit osteoblast proliferation (Ren and Dziak,
1991). Numerous studies have shown that prostaglandins stim-
ulate bone formation as well as bone resorption (Kawaguchi
et al., 1995). PGE2 synthesized from AA is a potent stimulator
of bone resorption and also inﬂuences the production and ac-
tion of insulin-like growth factor which is responsible for new
bone formation and matrix production during osteoclastic
bone resorptive activity (Linkhart et al., 1996; Watkins et al.,
2001). Some studies suggest that lower concentration of
PGE2 promote bone formation while higher concentrations in-
hibit it (Raisz and Fall, 1990; Watkins et al., 1997). The ratio
between x-6 and x-3 fatty acids also plays an important role in
bone health (Watkins et al., 2006). Among 1532 community-
dwelling men and women aged 45–90 years, a signiﬁcant in-
verse association between the ratio of dietary LA to ALA
and bone mineral density at the hip in men, in women not
using hormone therapy, and in women using hormone therapy
was found. A higher ratio of x-6 to x-3 fatty acids was asso-
ciated with lower bone mineral density at the hip in both sexes
(Weiss et al., 2005). A controlled feeding study in humans
(n= 23) evaluating the effect of dietary plant-derived x-3
PUFA on bone turnover, showed no difference in bone speciﬁc
alkaline phosphatase (BSAP) in individuals consuming the
ALA-rich diet and those consuming an American diet or a
LA-rich diet (Griel et al., 2007). The concentration of
N-telopeptides (NTx) was positively correlated with the pro-
inﬂammatory cytokine tumour necrosis factor (TNF) alphafor all three diets. It was reported that the plant x-3 PUFA
ALA may have a protective effect on bone metabolism via a
decrease in bone resorption in the presence of consistent levels
of bone formation (Griel et al., 2007). Fish consumption was
associated with very small differences in bone mineral density
and had no association with hip fracture risk (Virtanen et al.,
2010). CLA also has been reported to improve bone mass but
available studies are inconsistent which might be due to inter-
action between CLA and dietary calcium (Li and Watkins,
1998; Rahman et al., 2007).
There are two major factors inﬂuencing the risk of the devel-
opment of osteoporosis, ﬁrstly peak bonemass and secondly the
rate at which bone loss occurs in later years. Calcium and mag-
nesium are biologically interlocked with each other and their
deﬁciency affects osteoclastic and osteoblastic activities (Thom-
son Healthcare, 2001). In animals contradictory results were
found on the effect of PUFA on calcium absorption but in hu-
mans there are some older studies which showed positive effect
ofMCTs on calcium absorption (Kehayoglou et al., 1973; Tant-
ibhedhyangkul and Hashim, 1978) although not all studies ﬁnd
this (Huston et al., 1983; Haderslev et al., 2000).
5.7. Atopic dermatitis
Atopic dermatitis (AD) is a chronic itchy, inﬂammatory skin
disease (Vender, 2002) which may be due to a partial enzy-
matic defect in delta-6 desaturase (Kerscher and Korting,
1992) and is characterized by the symptoms like itching and
dryness, redness, swelling, ﬂaking, blistering, cracking, bleed-
ing or skin discolouration. For the past decades, the prevalence
of atopic dermatitis is on the rise (Willemaers et al., 1998).
EFAs play a vital role in skin structure and physiology. De-
creased concentrations of GLA and DGLA may lead to chan-
ged skin permeability and in turn contribute to AD (Horrobin,
1992, 2000). There are studies, which suggest that the x-6 fatty
acid GLA is effective for the treatment of atopic dermatitis. A
review identiﬁed by 12 trials of oral or topical borage oil for
the treatment of atopic dermatitis and one preventive trial
and the majority of studies showed at least a small degree of
efﬁcacy and can be used as an alternative treatment (Foster
et al., 2010). A randomized controlled trial of 500 mg/day
evening primrose oil (a source of GLA) for 5 months in pa-
tients with atopic dermatitis reported that 24 (96%) in the
GLA group and 8 (32%) patients of placebo group showed
improvements in atopic dermatitis (Senapati et al., 2008). Die-
tary studies have found an inverse association of consumption
of milk with the dermatitis symptoms (Perkin and Strachan,
2006; Kummelings et al., 2007). Pomegranate seed oil which
also promotes regeneration and strengthening of epidermis
by stimulating keratinocyte proliferation (Aslam et al., 2006)
is also a good source of CLA (Hora et al., 2003; McFarlin
et al., 2009) and associated with speciﬁc skin repair activity
(Aslam et al., 2006).
6. Side effects
6.1. Omega-3 fatty acids
Omega-3 fatty acids presented as ﬁsh oil are generally well tol-
erated but may cause some side effects. These are usually mild
and transient mostly including a ﬁshy after taste and gastroin-
testinal disturbances. Other symptoms include nausea, heart-
Role of some functional lipids in preventing diseases and promoting health 325burn or indigestion, and diarrhoea. These effects are mostly
dose-dependent. Some concern has been raised that x-3 fatty
acids increase the risk of bleeding, although a number of stud-
ies suggest that this is unlikely to occur (Peet and Horrobin,
2002; Su et al., 2003) even at a high dosage and in combination
with other anticoagulant medications (Eritsland et al., 1996).
Nevertheless doses greater than 3 g/day of ﬁsh oil (or high die-
tary ﬁsh intake) may inhibit platelet aggregation and increase
bleeding (Knapp, 1997), so care should be taken before the
consumption of x-3 fatty acids with antithrombotic therapies.
DHA has six double bonds and ﬁve methylene carbons and it
is highly prone to peroxidation (Cho et al., 1987; Kawai et al.,
2006). Exposure to DHA is known to block several ionic cur-
rents. Peroxidation products of DHA change cell membrane
ﬂuidity and thereby modify the activity of ion channels (Jude
et al., 2003). Meydani et al. (1991) indicated that although
long-term (>3 months) ﬁsh oil supplementation may be bene-
ﬁcial in reducing plasma total triglycerides; susceptibility of
plasma lipids to free radical attack is potentiated.
6.2. Omega-6 fatty acids
An improper ratio of x-6 to x-3 fatty acids may promote prob-
lems like inﬂammation as an increased amount of x-6 fatty
acids produces eicosanoids which are responsible for the for-
mation of thrombus and atheromas and which play a role in
inﬂammatory disorders (Simopoulos, 2008a,b).
6.3. Conjugated linoleic acid
Clarinol is a mixture of CLA isomers and is produced from
sunﬂower oil; it includes some cis-9, trans-11 CLA. Clarinol
was found to cause liver enlargement in female rats but this ef-
fect was reported to be reversible (Hagan, 2002) and no major
liver abnormalities have been reported in humans consuming
CLA although most of the studies were of short duration (Lar-
sen et al., 2003). Insulin resistance and increased oxidative
stress have been reported with the consumption of trans-10,
cis-12 CLA but not with a mixed preparation of cis-9, trans-
11 and trans-10, cis-12 CLA (Ritzenthaler et al., 2001; Riserus
et al., 2004).
6.4. Medium chain triglycerides
MCTs are well tolerated with no serious demonstrable side ef-
fects. Ingestion of larger amounts (>25–30 g) of MCTs causes
adverse gastrointestinal symptoms, including nausea, vomiting,
abdominal cramps, gastrointestinal discomfort, bloating, and
osmotic diarrhoea (Jeukendrup and Aldred, 2004). Due to
hyperosmolarity, MCTs cause a large inﬂux of ﬂuid into the
large intestines and initiate gastrointestinal problems (Bain-
bridge et al., 1999) and so it is generally advised to start MCTs
treatment gradually and to increase the amount over time.
6.5. Phytosterols
Phytosterols are generally considered safe and the side effect
associated with phytosterol and stanol is their interference with
the absorption of beta-carotenoids, while levels of fat soluble
vitamins A, D, K1 and E did not change (Hendriks et al.,
2001; Judd et al., 2002). Since beta-carotenoids are precursors
of vitamin A, reduced intake could affect vitamin A status.Thus it is advised that pregnant women and children do not
consume supplemental phytosterols (ACNFP, 2002b). It seems
unlikely that phytosterols induced beta carotenoid deﬁciency is
of much concern in other subgroups.7. Conclusion and future perspectives
Functional lipids are healthy dietary components with the po-
tential for inﬂuencing human health, lowering risk of diseases
and improving quality of life. As mentioned in this review, the
health beneﬁts could include reduced susceptibility to heart
disease, obesity, depression, Alzheimer’s disease, Parkinson’s
disease and atopic dermatitis. They have been proved to be
effective and are easily available and economical to include
in the food chain/diet. Nevertheless, more studies are required
to investigate and fully elucidate the doses, dietary intake and
the efﬁcacy and mechanisms of various functional lipids dis-
cussed. An understanding of the development of valid disease
biomarkers, clinical trials, and long-term effects of these lipids
in humans awaits further study.
References
AbuMweis, S.S., Barake, R., Jones, P., 2008. Plant sterols/stanols as
cholesterol lowering agents: a meta-analysis of randomized con-
trolled trials. Food Nutr. Res.. http://dx.doi.org/10.3402/
fnr.v52i0.1811.
ACNFP, 2002a. Cholesterol lowering: foods with added plant sterols.
London, pp. 1–2. Cited from <http://www.food.gov.uk/multi-
media/pdfs/acnfpcholesterolfactsheet.pdf>.
ACNFP, 2002b. Extension in the range of uses of phytosterol esters
in: opinion on an application under the novel food regulation to
extend the range of uses of phytosterol esters in food products. UK.
pp. 1–10. Cited from <http://www.food.gov.uk/multimedia/pdfs/
unilever.pdf>.
Angerer, P., Von Schacky, C., 2000. N-3 polyunsaturated fatty acids
and the cardiovascular system. Curr. Opin. Lipidol. 11 (1), 57–63.
Aslam, M.N., Lansky, E.P., Varani, J., 2006. Pomegranate as a
cosmeceutical source. Pomegranate fractions promote proliferation
and procollagen synthesis and inhibit matrix metalloproteinase-1
production in human skin cells. J. Ethnopharmacol. 103, 311–318.
Awika, J.M., Rooney, L.W., 2004. Sorghum phytochemicals and
their potential impact on human health. Phytochemistry 65, 1199–
1221.
Baba, N., Bracco, E.F., Hashim, S.A., 1982. Enhanced thermogenesis
and diminished deposition of fat in response to overfeeding with a
diet containing medium chain triglycerides. Am. J. Clin. Nutr. 35,
678–682.
Bach, A.C., Babayan, V.K., 1982. Medium-chain triglycerides: an
update. Am. J. Clin. Nutr. 36, 950–962.
Bach, A.C., Ingenbleek, Y., Frey, A., 1996. The usefulness of dietary
medium-chain triglycerides in body weight control: fact or fancy. J.
Lipid Res. 37, 708–726.
Bainbridge, J.L., Gidal, B.E., Melody, R., 1999. The ketogenic diet.
Pharmacotherapy 19, 782–786.
Barberger-Gateau, P., Letenneur, L., Deschamps, V., Peres, K.,
Dartigues, J.F., Renaud, S., 2002. Fish, meat, and risk of dementia:
cohort study. Br. Med. J. 325, 932–993.
Barberger-Gateau, P., Samieri, C., Feart, C., Plourde, M., 2011.
Dietary omega 3 polyunsaturated fatty acids and Alzheimer’s
disease: interaction with apolipoprotein E genotype. Curr. Alzhei-
mer Res. 8, 479–491.
Bhatnagar, D., Durrington, P.N., 2003. Omega-3 fatty acids: their
role in the prevention and treatment of atherosclerosis related risk
factors and complications. Int. J. Clin. Pract. 57, 305–314.
326 B. Alabdulkarim et al.Birch, E.E., Garﬁeld, S., Castaneda, Y., Hughbanks-Wheaton, D.,
Uauy, R., Hoffman, D., 2007. Visual acuity and cognitive
outcomes at 4 years of age in a double-blind, randomized trial of
long-chain polyunsaturated fatty acid-supplemented infant for-
mula. Early Hum. Dev. 83, 279–284.
Blasbalg, T.L., Hibbeln, J.R., Ramsden, C.E., Majchrzak, S.F.,
Rawlings, R.R., 2011. Changes in consumption of omega-3 and
omega-6 fatty acids in the United States during the 20th century.
Am. J. Clin. Nutr. 93, 950–962.
Boston, P.F., Bennett, A., Horrobin, D.F., Bennett, C.N., 2004.
Ethyl-EPA in Alzheimer’s disease – a pilot study. Prostaglandins
Leukot. Essent. Fatty Acids 71, 341–344.
Brenna, J.T., 2002. Efﬁciency of conversion of alpha-linolenic acid to
long chain n-3 fatty acids in man. Curr. Opin. Clin. Nutr. Metab.
Care 5, 127–132.
Burdge, G.C., 2004. Alpha-linolenic acid metabolism in men and
women: nutritional and biological implications. Curr. Opin. Clin.
Nutr. Metab. Care 7, 137–144.
Cater, N.B., Heller, H.J., Denk, M.A., l997. Comparison of the effects
of medium-chain triacylglycerols palm oil, and high oleic acid
sunﬂower oil on plasma triacylglycerol fatty acids and lipid and
lipoprotein concentrations in humans. Am. J. Clin. Nutr. 65, 41–45.
Chen, H., Zhang, S.M., Hernan, M.A., Willett, W.C., Ascherio, A.,
2003. Dietary intakes of fat and risk of Parkinson’s disease. Am. J.
Epidemiol. 157, 1007–1014.
Cheng, Z., Elmes, M., Kirkup, S.E., Abayasekara, D.R.E., Wathes,
D.C., 2004. Alteration of prostaglandin and agonist responsiveness
by n-6 polyunsaturated fatty acids in endometrial cells from late-
gestation ewes. J. Endocrinol. 182, 249–256.
Cho, S.Y., Miyashita, K., Miyazawa, T., Fujimoto, K., Kaneda, T.,
1987. Autoxidation of ethyl eicosapentaenoate and docosahexae-
noate. J. Am. Oil Chem. Soc. 64, 876–879.
De Lau, L.M., Bornebroek, M., Witteman, J.C., Hofman, A.,
Koudstaal, P.J., Breteler, M.M., 2005. Dietary fatty acids and the
risk of Parkinson disease: the Rotterdam study. Neurology 64,
2040–2045.
Dratz, E.A., Holte, L.L., 1993. The molecular spring model for the
function of docosahexaenoic acid (22:6, x-3) in biological mem-
brane. In: Sinclair, A., Gibson, R. (Eds.), Essential Fatty Acids and
Eicosanoids: Invited Papers from the Third International Congress.
AOCS Press, Champaign, IL, pp. 122–127.
Ebine, N., Demontry, I., Jia, X., Jones, P.J., 2006. Plant stanol
ascorbate esters reduce body weight gain through decreased energy
absorption in hamsters. Int. J. Obes. 30, 751–757.
Eilander, A., Hundscheid, D.C., Osendarp, S.J., Transler, C., Zock,
P.L., 2007. Effects of n-3 long chain polyunsaturated fatty acid
supplementation on visual and cognitive development throughout
childhood: a review of human studies. Prostaglandins Leukot.
Essent. Fatty Acids 76, 189–203.
Eritsland, J., Arnesen, H., Gronseth, K., Fjeld, N.B., Abdelnoor, M.,
1996. Effect of dietary supplementation with n-3 fatty acids on
coronary artery bypass graft patency. Am. J. Cardiol. 77, 31–36.
Eussen, S.R., de Jong, N., Rompelberg, C.J., Garssen, J., Verschuren,
W.M., Klungel, O.H., 2011. Dose-dependent cholesterol-lowering
effects of phytosterol/phytostanol-enriched margarine in statin
users and statin non-users under free-living conditions. Public
Health Nutr. 14, 1823–1832.
FAO, 2008. Fats and fatty acids in human nutrition. Report of an
expert consultation. Food and Nutrition paper, 10–14 November,
Geneva. pp. 1–161.
Foster, R.H., Hardy, G., Alany, R.G., 2010. Borage oil in the
treatment of atopic dermatitis. Nutrition 26, 708–718.
Fotuhi, M., Mohassel, P., Yaffe, K., 2009. Fish consumption, long-
chain omega-3 fatty acids and risk of cognitive decline or
Alzheimer disease: a complex association. Nat. Clin. Pract. Neurol.
5, 140–152.
Gallwitz, W.E., Mundy, G.R., Lee, C.H., Qiao, M., Roodman, G.D.,
Raftery, M., Gaskell, S.J., Bonewald, L.F., 1993. 5-Lipoxygenasemetabolites of arachidonic acid stimulate isolated osteoclasts to
resorb calciﬁed matrices. J. Biol. Chem. 268, 10087–10094.
Griel, A.E., Kris Etherton, P.M., Hilpert, K.F., Zhao, G., West, S.G.,
Corwin, R.L., 2007. An increase in dietary n-3 fatty acids decreases
a marker of bone resorption in humans. J. Nutr. 16, 1–2.
Haderslev, K.V., Jeppensen, P.B., Mortensen, P.B., Staun, M., 2000.
Absorption of calcium and magnesium in patients with intestinal
resections treated with medium chain fatty acids. Gut 46, 819–823.
Hadjidakis, D.J., Androulakis, I.I., 2006. Bone remodelling. Ann.
N.Y. Acad. Sci. 1092, 385–396.
Hagan, S.O., 2002. Toxicology studies on clarinol. In: Perspectives on
Conjugated Linoleic Acid Research, Current Status and Future
Directions. Lister Hill Auditorium, Bethesda, Maryland, p. 14.
Hardman, W.E., 2004. (n-3) Fatty acids and cancer therapy. J. Nutr.
Suppl., 3427S–3430S.
Harris, W.S., 1997. N-3 fatty acids and serum lipoproteins: human
studies. Am. J. Clin. Nutr. 65, 1645S–1654S.
Hendriks, H.F., Ntanios, F., Brink, E.J., Princen, H.M., Buytenket,
D.R., Meijer, G.W., 2001. One-year follow-up study on the use of a
low fat spread enriched with plant sterol-esters. Ann. Nutr. Metab.
45, 100.
Hoffer, L.J., Bistrian, B.R., Young, V.R., Blackburn, G.L., Mat-
thews, D.E., 1984. Metabolic effects of very low calorie weight
reduction diets. J. Clin. Invest. 73, 750–758.
Hora, J.J., Maydew, E.R., Lansky, E.P., Dwivedi, C., 2003. Chemo-
preventive effects of pomegranate seed oil on skin tumor develop-
ment in CD1 mice. J. Med. Food 6, 157–161.
Horrobin, D.F., 1992. Nutritional and medical importance of
gamma-linolenic acid. Prog. Lipid Res. 31, 163–194.
Horrobin, D.F., 2000. Essential fatty acid metabolism and its
modiﬁcation in atopic eczema. Am. J. Clin. Nutr. 71, 367S–372S.
Horrobin, D.F., 2001. Phospholipid metabolism and depression: the
possible roles of phospholipase A2 and coenzyme A-independent
transacylase. Hum. Psychopharmacol. 16, 45–52.
Horrobin, D.F., Bennett, C.N., 1999. Depression and bipolar
disorder: relationships to impaired fatty acid and phospholipids
metabolism and to diabetes, cardiovascular disease, immunological
abnormalities, cancer, ageing and osteoporosis. Possible candidate
genes. Prostaglandins Leukot. Essent. Fatty Acids 60, 217–234.
Huston, R.K., Reynolds, J.W., Jensen, C., Buist, N.R., 1983.
Nutrient and mineral retention and vitamin D absorption in low-
birth-weight infants: effect of medium-chain triglycerides. Pediat-
rics 72, 44–48.
Igarashi, M., Ma, K., Chang, L., Bell, J.M., Rapoport, S.I., De Mar
Jr, J.C., 2006. Low liver conversion rate of a-linolenic to docosa-
hexaenoic acid in awake rats on a high-docosahexaenoate-contain-
ing diet. J. Lipid Res. 47, 1812–1822.
Innis, S.M., 2003. Perinatal biochemistry and physiology of long-
chain polyunsaturated fatty acids. J. Pediatr. 143, S1–S8.
Ip, C., Scimec, J.A., Thompson, H.J., 1994. Conjugated linoleic acid.
A powerful anticarcinogen from animal fat sources. Cancer 233,
1050–1054.
Jacobson, T.A., 2008. Role of n-3 fatty acids in the treatment of
hypertriglyceridemia and cardiovascular disease. Am. J. Clin. Nutr.
87, 1981S–1990S.
Jeukendrup, A.E., Aldred, S., 2004. Fat supplementation, health, and
endurance performance. Nutrition 20, 678–688.
Jicha, G.A., Markesbery, W.R., 2010. Omega-3 fatty acids: potential
role in the management of early Alzheimer’s disease. Clin. Interv.
Aging 5, 45–61.
Judd, J.T., Baer, D.J., Chen, S.C., Clevidence, B.A., Muesing, R.A.,
Kramer, M., Meijer, G.W., 2002. Plant sterol esters lower plasma
lipids and most carotenoids in mildly hypercholesterolemic adults.
Lipids 37, 33–42.
Jude, S., Bedut, S., Roger, S., Pinault, M., Champeroux, P., White,
E., Le Guennec, J.Y., 2003. Peroxidation of docosahexaenoic acid
is responsible for its effects on ITO and ISS in rat ventricular
myocytes. Br. J. Pharmacol. 139, 816–822.
Role of some functional lipids in preventing diseases and promoting health 327Kalmijn, S., van Boxtel, M.P.J., Ocke, M., Verschuren, W.M.M.,
Kromhout, D., Launer, L.J., 2004. Dietary intake of fatty acids and
ﬁsh in relation to cognitive performance at middle age. Am. Acad.
Neurol. 62, 275–280.
Kamphuis, M.M., Lejeune, M.P., Saris, W.H., Plantenga, M.S.W.,
2003. Effect of conjugated linoleic acid supplementation after
weight loss on appetite and food intake in overweight subjects. Eur.
J. Clin. Nutr. 57, 1268–1274.
Kapoor, R., Patil, U.K., 2011. Importance and production of omega-
3 fatty acids from natural sources. Int. Food Res. J. 18, 493–499.
Kawaguchi, H., Pilbeam, C.C., Harrison, J.R., Raisz, L.G., 1995. The
role of prostaglandins in the regulation of bone metabolism. Clin.
Orthop. Relat. Res. 313, 36–46.
Kawai, Y., Fujii, H., Okada, M., Tsuchie, Y., Uchida, K., Osawa, T.,
2006. Formation of Nepsilon-(succinyl) lysine in vivo: a novel
marker for docosahexaenoic acid-derived protein modiﬁcation. J.
Lipid Res. 47, 1386–1398.
Kehayoglou, K., Hadziyannis, S., Kostamis, P., Malamos, B., 1973.
The effect of medium-chain triglyceride on 47 calcium absorption
in patients with primary biliary cirrhosis. Gut 14, 653–656.
Kerscher, M.J., Korting, H.C., 1992. Treatment of atopic eczema
with evening primrose oil: rationale and clinical results. Clin.
Invest. 70, 167–171.
Kitts, D.D., 2005. Toxicity and safety of fats and oils. In: Fereidoon,
Shahidi (Ed.), Bailey’s Industrial Oil and Fat Products, sixth
edition, six volume set. University of British Columbia, Vancouver,
British Columbia, Canada, pp. 513–564.
Knapp, H.R., 1997. Dietary fatty acids in human thrombosis and
haemostasis. Am. J. Clin. Nutr. 65, 1687S–1698S.
Kohli, P., Levy, B.D., 2009. Resolvins and protectins: mediating
solutions to inﬂammation. Br. J. Pharmacol. 158, 960–971.
Kris-Etherton, P.M., Harris, W.S., Appel, L.J., 2002. Fish consump-
tion, ﬁsh oil, omega-3 fatty acids, and cardiovascular disease.
Circulation 106, 2747–2757.
Krotkiewski, M., 2001. Value of VLCD supplementation with
medium chain triglycerides. Int. J. Obes. 25, 1393–1400.
Kummelings, I., Thijis, C., Huber, M., van de Vijver, L.P., Snijdes,
B.E., Penders, J., Stelma, F., van Ree, R., van den Brandt, P.A.,
Dagnelie, P.C., 2007. Consumption of organic foods and risk of
atopic disease during the ﬁrst two year of life in Netherland. Br. J.
Nutr. 29, 1–8.
Kunesova, M., Braunerova, R., Hlavaty, P., Tvrzicka, E., Stankova,
B., Skrha, J., Hilgertova, J., Hill, M., Kopecky, J., Wagenknecht,
M., Hainer, V., Matoulek, M., Parizkova, J., Zak, A., Svacina, S.,
2006. The inﬂuence of n-3 polyunsaturated fatty acids and very low
calorie diet during a short-term weight reducing regimen on weight
loss and serum fatty acid composition in severely obese women.
Physiol. Res. 55, 63–72.
Larsen, T.M., Toubro, S., Astrup, A., 2003. Efﬁcacy and safety of
dietary supplement containing Conjugated Linoleic Acid (CLA) for
the treatment of obesity-evidence from animal and human studies.
J. Lipid Res. 44, 2234–2241.
Larsen, T.M., Toubro, S., Gudmundsen, O., Astrup, A., 2006.
Conjugated linoleic acid supplementation for 1 y does not prevent
weight or body fat regain. Am. J. Clin. Nutr. 83, 606–612.
Law, M.R., 2000. Plant sterol and stanol margarines and health.
West. J. Med. 173, 43–47.
Leaf, A., Kang, J.X., Xiao, Y.F., Billman, G.E., 2003. Clinical
prevention of sudden cardiac death by n-3 polyunsaturated fatty
acids and mechanism of prevention of arrhythmias by n-3 ﬁsh oils.
Circulation 107, 2646–2652.
Lee, K.W., Lip, G.Y.H., 2003. The role of omega-3 fatty acids in the
secondary prevention of cardiovascular disease. Q. J. Med. 96 (7),
465–480.
Levant, B., 2010. N-3 (omega-3) fatty acids in postpartum depression:
implications for prevention and treatment. Depress. Res. Treat.
2011, 1–16.Li, Y., Watkins, B.A., 1998. Conjugated linoleic acids alter bone fatty
acids composition and reduce ex vivo prostaglandins E2 biosyn-
thesis in rats fed n-6 and n-3 fatty acids. Lipids 33, 417–425.
Lichtenstein, A.H., Deckelbaum, R.J., 2001. Stanol/sterol ester-
containing foods and blood cholesterol levels. Circulation 103,
1177–1179.
Linkhart, T.A., Mohan, S., Baylink, D.J., 1996. Growth factors for
bone growth and repair: IGF, TGF beta and BMP. Bone 19, 1–12.
Losso, J.N., 2003. Targeting excessive angiogenesis with functional
foods and nutraceuticals. Trends Food Sci. Technol. 14, 455–468.
Maccioni, R.B., Munoz, J.P., Barbeito, L., 2001. The molecular bases
of Alzheimer’s disease and other neurodegenerative disorders.
Arch. Med. Res. 32, 367–381.
Malpuech-Brugere, C., Verboeket-van de Venne, W.P., Mensink,
R.P., Arnal, M.A., Morio, B., Brandolini, M., Saebo, A., Lassel,
T.S., Chardigny, J.M., Sebedio, J.L., Beaufrere, B., 2004. Effects of
two conjugated linoleic acid isomers on body fat mass in
overweight humans. Obes. Res. 12, 591–598.
Marten, B., Pfeuffer, M., Schrezenmeir, J., 2006. Medium-chain
triglycerides. Int. Dairy J. 16, 1374–1382.
McFarlin, B.K., Strohacker, K.A., Kueht, M.L., 2009. Pomegranate
seed oil consumption during a period of high-fat feeding reduces
weight gain and reduces type 2 diabetes risk in CD-1 mice. Br. J.
Nutr. 102, 54–59.
McNamara, R.K., Carlson, S.E., 2006. Role of omega-3 fatty acids in
brain development and function: potential implications for the
pathogenesis and prevention of psychopathology. Prostaglandins
Leukot. Essent. Fatty Acids 75, 329–349.
Mensink, R.P., Zock, P.L., Kester, A.D.M., Katan, M.B., 2003.
Effects of dietary fatty acids and carbohydrates on the ratio of
serum total to HDL cholesterol and on serum lipids and apolipo-
proteins: a meta-analysis of 60 controlled trials. Am. J. Clin. Nutr.
77, 1146–1155.
Meydani, M., Natiello, F., Goldin, B., Free, N., Woods, M.,
Schaefer, E., Blumberg, J.B., Gorbach, S.L., 1991. Effect of long-
term ﬁsh oil supplementation on vitamin E status and lipid
peroxidation in women. J. Nutr. 121, 484–491.
Miller, R.L., James-Kracke, M., Sun, G.Y., Sun, A.Y., 2009.
Oxidative and inﬂammatory pathways in Parkinson’s disease.
Neurochem. Res. 34, 55–65.
Moreau, R.A., 2011. An overview of functional lipids. In: 102nd
AOCS Annual Meeting and Expo, Duke Energy Center, Cincin-
nati, Ohio, USA.
Mori, T.A., Beilin, L.J., 2004. Omega-3 fatty acids and inﬂammation.
Curr. Atheroscler. Rep. 6, 461–467.
Morley, J.E., Banks, W.A., 2010. Lipids and cognition. J. Alzheimers
Dis. 20, 737–747.
Morris, M.C., Evans, D.A., Bienias, J.L., Tangney, C.C., Bennett,
D.A., Wilson, R.S., Aggarwal, N., Schneider, J., 2003. Consump-
tion of ﬁsh and n-3 fatty acids and risk of incident Alzheimer
disease. Arch. Neurol. 60, 940–946.
Mougios, V., Matsakas, A., Petridou, A., Ring, S., Sagredos, A.,
Melissopoulou, A., Tsigilis, N., Nikolaidis, M., 2001. Effect of
supplementation with conjugated linoleic acid on human serum
lipids and body fat. J. Nutr. Biochem. 12, 585–594.
Nagao, K., Yanagita, T., 2005. Conjugated fatty acids in food and
their health beneﬁts. J. Biosci. Bioeng. 100, 152–157.
Ng, K.W., Romas, E., Donnan, L., Findlay, D.M., 1997. Bone
biology. Baillieres Clin. Endocrinol. Metab. 11, 1–22.
Olanow, C.W., Tatton, W.G., 1999. Etiology and pathogenesis of
Parkinson’s disease. Annu. Rev. Neurosci. 22, 123–144.
Parra, D., Ramel, A., Bandarra, N., Kiely, M., Martinez, J.A.,
Thorsdottir, I., 2008. A diet rich in long chain omega 3 fatty acids
modulates satiety in overweight and obese volunteers during weight
loss. Appetite 51, 676–680.
Peet, M., Horrobin, D.F., 2002. A dose-ranging study of the effects of
ethyl-eicosapentaenoate in patients with ongoing depression despite
328 B. Alabdulkarim et al.apparently adequate treatment with standard drugs. Arch. Gen.
Psychiatry 59, 913–919.
Perkin, M.R., Strachan, D.P., 2006. Which aspect of farming lifestyle
explains the inverse association with childhood allergy. J. Allergy
Clin. Immunol. 117, 1374–1381.
Pirronen, V., Lindsay, D.G., Miettinen, T.A., Tovio, J., Lampi, A.M.,
2000. Review plant sterols: biosynthesis, biological function and
their importance to humannutrition. J. Sci. FoodAgric. 80, 939–966.
Puri, B.K., 2005. Nutrients, Stress and Medical Disorder, Nutrition
and Health: Lipids and Depression. Human Press Inc., Totowa,
NJ.
Rahman, M.M., Bhattacharya, A., Fernandes, B.J., 2007. Conju-
gated linolenic acid protects against age associated bone loss in
C57BL/6 female mice. J. Nutr. Biochem. 18, 467–474.
Raisz, L.G., Fall, P.M., 1990. Biphasic effects of prostaglandin E2 on
bone formation in cultured fetal rat calvariae: interaction with
cortisol. Endocrinology 126, 1654–1659.
Ren, W., Dziak, R., 1991. Effects of leukotrienes on osteoblastic cell
proliferation. Calcif. Tissue Int. 49, 197–201.
Riserus, U., Smedman, A., Basu, S., Vessby, B., 2004. Metabolic
effects of conjugated linoleic acid in humans: the Swedish experi-
ence. Am. J. Clin. Nutr. 79, 1146S–1148S.
Ritzenthaler, K.L., McGuire, M.K., Falen, R., Shultz, T.D.,
Dasgupta, N., McGuire, M.A., 2001. Estimation of conjugated
linoleic acid intake by written dietary assessment methodologies
underestimates actual intake evaluated by food duplicate method-
ology. J. Nutr. 131, 1548–1554.
Roberfroid, M.B., 2000. Concepts and strategy of functional food
science: the European perspective. Am. J. Clin. Nutr. 71, 1660S–
1665S.
Robinson, D.R., Tateno, S., Patel, B., Hirai, A., 1988. Lipid
mediators of inﬂammatory and immune reactions. J. Parenter.
Enteral Nutr. 12, S37–S42.
Ryder, J.W., Portocarrero, C.P., Song, X.M., Cui, L., Combatsiaris,
T.Y.M., Galusk, O., Bavman, D.E., Barbano, D.M., Charron,
M.J., Zierath, T.R., Housekuncht, K.L., 2001. Isomerspeciﬁc
antidiabetic properties of CLA. Improved glucose tolerance,
skeletal muscle insulin and VCP-2 gene expression. Diabetes 50,
1149–1157.
San Giovanni, J.P., Chew, E.Y., 2005. The role of omega-3 long chain
polyunsaturated fatty acids in health and disease of retina. Prog.
Retin. Eye Res. 24, 87–138.
Sastry, R.S., 1985. Lipids of nervous tissue: composition and
metabolism. Prog. Lipid Res. 24, 69–176.
Sehat, N., Kramer, J.K.G., Mossoba, M.M., Yuraweez, M.P.,
Roach, J.A.G., Eulitz, K., Morehouse, K.M., Ku, Y., 1999.
Identiﬁcation of conjugated linoleic acid isomers in cheese by gas
chromatography, silver ion high performance liquid chromatogra-
phy and mass spectral reconstructed ion proﬁles. Comparison of
chromatographic elution sequences. Lipids 33, 963–971.
Seki, S., Hidaka, I., Kojima, K., Yoshino, H., Aoyama, T., Okazaki,
M., Kondo, K., 2003. Effects of phytosterol ester-enriched vege-
table oil on plasma lipoproteins in healthy men. Asia Pac. J. Clin.
Nutr. 12, 282–291.
Senapati, S., Banerjee, S., Gangopadhyay, D.N., 2008. Evening
primrose oil is effective in atopic dermatitis: a randomized placebo-
controlled trial. Indian J. Dermatol. Venereol. Leprol. 74, 447–
452.
Simopoulos, A.P., 1991. Omega 3 fatty acids in health and disease
and in growth and development. Am. J. Clin. Nutr. 54, 438–463.
Simopoulos, A.P., 2002. Omega-3 fatty acids in inﬂammation and
autoimmune diseases. J. Am. Coll. Nutr. 21, 495–505.
Simopoulos, A.P., 2003. Importance of the ratio of omega 6/omega 3
essential fatty acids: evolutionary aspects. World Rev. Nutr. Diet.
92, 1–174.
Simopoulos, A.P., 2008a. The omega 6/omega 3 fatty acids ratio,
genetic variation, and cardiovascular disease. Asia Pac. J. Clin.
Nutr. 17, 131–134.Simopoulos, A.P., 2008b. The importance of omega 6/omega 3 fatty
acids in cardiovascular diseases and other chronic diseases. Exp.
Biol. Med. 233, 674–688.
Simopoulos, A.P., 2010. Genetic variants in the metabolism of
omega-6 and omega-3 fatty acids: their role in the determination of
nutritional requirements and chronic disease risk. Exp. Biol. Med.
235, 785–795.
Simopoulos, A.P., Leaf, A., Salem, N.J., 2000. Workshop statement
on the essentiality of and recommended dietary intakes for omega-6
and omega-3 fatty acids. Prostaglandins Leukot. Essent. Fatty
Acids 63, 119–121.
Sinclair, A.J., Begg, D., Mathai, M., Weisinger, R.S., 2007. Omega 3
fatty acids and the brain: review of studies in depression. Asia Pac.
J. Clin. Nutr. 16, 391–397.
Smedman, A., Vessby, B., 2001. CLA supplementation in humans-
metabolic effects. J. Nutr. 36, 773–781.
Smits, B.J., Wilding, P., Cooke, W.T., 1968. Ready absorption of
medium chain triglyceride in the steatorrhoea syndrome. Gut 9, 28–
33.
Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q.,
Jakes, R., Goedert, M., 1997. Alpha-synuclein in Lewy bodies.
Nature 388, 839–840.
Stahl, L.A., Begg, D.P., Weisinger, R.S., Sinclair, A.J., 2008. The role
of omega-3 fatty acids in mood disorders. Curr. Opin. Investig.
Drugs 9, 57–64.
Stein, J., 1999. Chemically deﬁned structured lipids: current status
and future directions in gastrointestinal diseases. Int. J. Colorectal
Dis. 14, 79–85.
Su, B., Wang, X., Zheng, L., Perry, G., Smith, M.A., Zhu, X., 2010.
Abnormal mitochondrial dynamics and neurodegenerative dis-
eases. Biochim. Biophys. Acta 1802, 135–142.
Su, K.P., Huang, S.Y., Chiu, C.C., Shenc, W.W., 2003. Omega-3
fatty acids in major depressive disorder: a preliminary double-
blind, placebo-controlled trial. Eur. Neuropsychopharm. 13 (4),
267–271.
Sun, D., Krishnan, A., Zaman, K., Lawrence, R., Bhattacharya, A.,
Fernandes, G., 2003. Dietary n-3 fatty acids decreases osteoclasto-
genesis and loss of bone mass in ovariectomized mice. J. Bone
Miner. Res. 18, 1206–1216.
Svensson, M., Christensen, J.H., Solling, J., Schmidt, E.B., 2004. The
effect of n-3 fatty acids on plasma lipids and lipoproteins and blood
pressure in patients with CRF. Am. J. Kidney Dis. 44, 77–83.
Tantibhedhyangkul, P., Hashim, S.A., 1978. Medium-chain triglyc-
eride feeding in premature infants: effects on calcium and magne-
sium absorption. Paediatrics 61, 537–545.
Tapiero, H., Ba, G.N., Couvreur, P., Tew, K.D., 2002. Polyunsat-
urated fatty acids (PUFA) and eicosanoids in human health and
pathologies. Biomed. Pharmacother. 56, 215–222.
Taziki, O., Pezeshki, M.L., Akha, O., Vasheghani, F., 2007. The
effect of low dose omega-3 on plasma lipids in hemodialysis
patients. Saudi J. Kidney Dis. Transplant. 18, 571–576.
Terpstra, A.H.M., 2004. Effect of conjugated linoleic acid on body
composition and plasma lipids in humans: an overview of the
literature. Am. J. Clin. Nutr. 79, 352–361.
Thomson Healthcare, 2001. PDR for Nutritional Supplements.
Medical Economics Company Inc., Montvale, NJ.
Thornton, S.J., Wong, I.T., Neumann, R., Kozlowski, P., Wasan,
K.M., 2011. Dietary supplementation with phytosterol and ascor-
bic acid reduces body mass accumulation and alters food transit
time in a diet-induced obesity mouse model. Lipids Health Dis. 28,
107.
Thorsdottir, I., Tomasson, H., Gunnarsdottir, I., Gisladottir, E.,
Kiely, M., Parra, M.D., Bandarra, N.M., Sachafsma, G., Martinez,
J.A., 2007. Randomized trial of weight-loss-diets for young adults
varying in ﬁsh and ﬁsh oil content. Int. J. Obes. 31, 1560–1566.
Umhau, J.C., Zhou, W., Carson, R.E., Rapoport, S.I., Polozova, A.,
Demar, J., Hussein, N., Bhattacharjee, A.K., Ma, K., Esposito, G.,
Majchrzak, S., Herscovitch, P., Eckelman, W.C., Kurdziel, K.A.,
Role of some functional lipids in preventing diseases and promoting health 329Salem, . Imaging incorporation of circulating docosahexaenoic acid
into the human brain using positron emission tomography. J. Lipid
Res. 50, 1259–1268.
Vender, R.B., 2002. Alternative treatments for atopic dermatitis: a
selected review. Skin Therapy Lett. 7, 1–8.
Virtanen, J.K., Mozaffarian, D., Cauley, J.A., Mukamal, K.J.,
Robbins, J., Siscovick, D.S., 2010. Fish consumption, bone mineral
density, and risk of hip fracture among older adults: the cardio-
vascular health study. J. Bone Miner. Res. 25, 1972–1979.
Vrablik, J.K., Prusikova, M., Snejdrlova, M., Zlatohlavek, L., 2009.
Omega-3 fatty acids and cardiovascular disease risk: Do we
understand the relationship? Physiol. Res. 58, 19–26.
WHO, 2011. Depression. Mental Health, pp. 1–2.Cited from<http://
www.who.int/mental_health/management/depression/deﬁnition/
en/>.
Watkins, B.A., Shen, C.L., Mc Murtry, J.P., Xu, H., Bain, S.D.,
Allen, K.G., Seifert, M.F., 1997. Dietary lipids modulate bone
prostaglandin E2 production, insulin-like growth factor-I concen-
tration and formation rate in chicks. J. Nutr. 127, 1084–1091.Watkins, B.A., Lippman, H.E., LeBouteiller, L., Li, Y., Seifert, M.F.,
2001. Bioactive fatty acids: role in bone biology and bone cell
function. Prog. Lipid Res. 40, 125–148.
Watkins, B.A., Lippman, H.E., Feng, S., 2003. Modulatory effect of
omega-3polyunsaturated fatty acidsonosteoblast functionandbone
metabolism. Prostaglandins Leukot. Essent. Fatty Acids 6, 387–398.
Watkins, B.A., Li, Y., Seifert, M.F., 2006. Dietary ratio of n-6/n-3
PUFAs and docosahexaenoic acid: actions on bone mineral and
serum biomarkers in ovariectomized rats. J. Nutr. Biochem. 17,
282–289.
Weiss, L.A., Connor, E.B., vonMuhlen, D., 2005. Ratio of n-6 to n-3
fatty acids and bone mineral density in older adults: the Rancho
Bernardo Study. Am. J. Clin. Nutr. 81, 934–938.
Wheelan, J., 1996. Antagonistic effects of dietary arachidonic acid
and n-3 polyunsaturated fatty acids. J. Nutr. 12, 1086S–1091S.
Willemaers, V., Stas, I., Pierard-Franchimont, C., Cornil, F., Pierard,
G.E., 1998. Atopic dermatitis. Rev. Med. Liege 53, 67–70.
Williams, C.M., Burdge, G., 2006. Long-chain n-3 PUFA: plant v
marine sources. Proc. Nutr. Soc. 65, 42–50.
